At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Unity-based MR-Linac guided FSRTcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Phase II Study of MR-Linac Guided Adaptive Fractionated Stereotactic Radiotherapy for Brain Metastases From Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Unity-based MR-Linac guided FSRT for Non-small Cell Lung Cancer. Completed, enrolled 55 participants across 1 site.
Detailed Summary
This Phase II study is to determine the efficacy and safety of MR-Linac Guided Adaptive fractionated stereotactic radiotherapy (FSRT) in patients with brain metastases in non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedJun 2021
Primary CompletionJul 2024
TodayJul 2026
First PostedJun 30, 2021
Enrollment StartJun 1, 2021
Primary CompletionJul 17, 2024
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 5.0 years ago
Interventions
Unity-based MR-Linac guided FSRTcombination
The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.